 |
|
|
|
|
OUR TEAM
Henrik Sandvad Rasmussen | Partner
Henrik Sandvad Rasmussen joined Ventac Partners in December 2011. Henrik received his MD/PhD from University of Copenhagen, Denmark. After 5 years of clinical practice at a major University hospital in Denmark, Dr. Rasmussen has spent the last 24 years in the biotech and pharmaceutical industry in senior and executive level positions within clinical development, medical and regulatory affairs in big pharma (Pfizer, Novo Nordisk) as well as biotech (British Biotech, Genvec and Nabi). He has experience in the development of small molecules (Pfizer, British Biotech) as well as biologics (GenVec, Nabi, Novo Nordisk) within a number of different therapeutic areas, such as cardiovascular, diabetes, metabolism, oncology, neurology, infectious diseases, gastroenterology, blood and plasma products, vaccines, ophthalmology, and dermatology. Most recently, Dr. Rasmussen was Head of Clinical Development, Regulatory and Medical Affairs for Novo Nordisk North America. Dr. Rasmussen has been responsible for numerous regulatory filings worldwide including several INDs, CTAs, NDAs, sNDAs, BLA and MAA filings. Dr. Rasmussen has published more than 150 full papers, reviews, book chapters and abstracts in peer-reviewed medical journals, including The Lancet, Lancet Oncology, British Medical Journal, Archives of Internal Medicine, Journal of Clinical Oncology, Gastroenterology, Circulation, American Journal of Cardiology etc. and is the holder of 4 patents.
Return to Our Team page
